These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29372886)

  • 1. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment.
    Bigliano P; Calcagno A; Lucchini A; Audagnotto S; Montrucchio C; Marinaro L; Alcantarini C; Ghisetti V; Di Perri G; Bonora S
    Antivir Ther; 2018; 23(5):451-456. PubMed ID: 29372886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
    Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
    Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
    Wohl DA; Kendall MA; Andersen J; Crumpacker C; Spector SA; Feinberg J; Alston-Smith B; Owens S; Chafey S; Marco M; Maxwell S; Lurain N; Jabs D; Benson C; Keiser P; Jacobson MA;
    HIV Clin Trials; 2009; 10(3):143-52. PubMed ID: 19632953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.
    Mihăilescu R; Arama V; Paraschiv S; Streinu-Cercel A; Oţelea D; Munteanu D; Iosipenco M; Chiotan C; Benea OE; Mărdărescu M; Rădulescu M; Hristea A; Ungurianu R; Aramă SS; Cercel AS; Călin R; Băicuş C
    Rom J Intern Med; 2008; 46(4):305-11. PubMed ID: 19480296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
    Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
    Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
    Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy.
    Deayton J; Mocroft A; Wilson P; Emery VC; Johnson MA; Griffiths PD
    AIDS; 1999 Jul; 13(10):1203-6. PubMed ID: 10416523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and determinants of cytomegalovirus induced end organ disease/s among people living with HIV/AIDS in a poor resource setting: observation from India.
    Chakraborty A; Mahapatra T; Mahapatra S; Ansari S; Siddhanta S; Banerjee S; Banerjee D; Sarkar RN; Guha SK; Chakraborty N
    PLoS One; 2015; 10(2):e0117466. PubMed ID: 25679798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis.
    Macdonald JC; Karavellas MP; Torriani FJ; Morse LS; Smith IL; Reed JB; Freeman WR
    Ophthalmology; 2000 May; 107(5):877-81; discussion 881-3. PubMed ID: 10811078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
    Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
    J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy.
    Song MK; Karavellas MP; MacDonald JC; Plummer DJ; Freeman WR
    Retina; 2000; 20(2):151-5. PubMed ID: 10783947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1.
    Komanduri KV; Viswanathan MN; Wieder ED; Schmidt DK; Bredt BM; Jacobson MA; McCune JM
    Nat Med; 1998 Aug; 4(8):953-6. PubMed ID: 9701250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.
    Whitcup SM; Fortin E; Lindblad AS; Griffiths P; Metcalf JA; Robinson MR; Manischewitz J; Baird B; Perry C; Kidd IM; Vrabec T; Davey RT; Falloon J; Walker RE; Kovacs JA; Lane HC; Nussenblatt RB; Smith J; Masur H; Polis MA
    JAMA; 1999 Nov; 282(17):1633-7. PubMed ID: 10553789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical characteristics and T-lymphocyte subsets in 48 acquired immune deficiency syndrome patients with cytomegalovirus infections].
    Jia CH; Wang L; Jing FH; Xie J; Qiu ZF; Li TS; Lyu W
    Zhonghua Nei Ke Za Zhi; 2019 Mar; 58(3):191-197. PubMed ID: 30803177
    [No Abstract]   [Full Text] [Related]  

  • 16. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
    Bronke C; Palmer NM; Jansen CA; Westerlaken GH; Polstra AM; Reiss P; Bakker M; Miedema F; Tesselaar K; van Baarle D
    J Infect Dis; 2005 Mar; 191(6):873-80. PubMed ID: 15717261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial.
    Chanouzas D; Dyall L; Nightingale P; Ferro C; Moss P; Morgan MD; Harper L
    Trials; 2016 Jul; 17(1):338. PubMed ID: 27450392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMV pp65 antigen testing is of limited utility in the diagnosis of concomitant CMV disease in HIV-infected patients in the HAART era.
    Skiest DJ; Crosby C
    J Clin Virol; 2003 Oct; 28(2):203-13. PubMed ID: 12957190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from HIV pathogenesis and therapy: implications for better management of cytomegalovirus disease.
    Hardy WD
    AIDS; 1996 Nov; 10 Suppl 1():S31-5. PubMed ID: 8970674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between cytomegalovirus retrieved by bronchoalveolar lavage and mortality in patients with HIV.
    Hayner CE; Baughman RP; Linnemann CC; Dohn MN
    Chest; 1995 Mar; 107(3):735-40. PubMed ID: 7874946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.